ArticleJHEP reports : innovation in hepatology2025
Utility of tumor and non-tumor biopsies during percutaneous radiofrequency ablation for hepatocellular carcinoma.
Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03071458 (Translating Molecular Classifications and Genetic Alterations of Hepatocellular Carcinoma in Clinical Care), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Translating Molecular Classifications and Genetic Alterations of Hepatocellular Carcinoma in Clinical Care (MUTHEC Project)
Who cites it
1 citing paper in PubMed.
- Fine needle aspirates characterise the hepatocellular carcinoma immune niche to predict immune checkpoint inhibitor outcomes.JHEP reports : innovation in hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: We aimed to assess the safety and diagnostic/prognostic value of tumor and non-tumor biopsies systematically collected during radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC). Methods: We prospectively included patients with a first diagnosis of HCC who underwent tumor and non-tumor biopsies during percutaneous RFA between 2015 and 2021. We analyzed the complications, percentage of diagnostic tumor biopsies, ability to perform molecular biology, and the non-tumor liver biopsy results, and correlated histology with prior non-invasive diagnosis and oncological outcomes. Results: In total, 248 patients (86% male, median age 68) with 302 tumors treated by RFA and with available tumor biopsy were included. HCC was single in 78% and bifocal in 21% of patients, with a median size of 24 mm. Bleeding occurred in six cases (1.9%) without related deaths. Biopsies enabled HCC diagnosis in 66% of cases, with positivity linked to nodule size ( Conclusion: Systematic tumor and non-tumor biopsy during RFA for a first diagnosis of HCC is feasible, safe, and brings valuable diagnostic, therapeutic, and prognostic data. Impact and implications: Tumor and non-tumor biopsies during radiofrequency ablation for hepatocellular carcinoma are both safe and feasible, with a low complication rate and no procedure-related deaths. We demonstrated the diagnostic utility of biopsies, revealing discrepancies in 5% of cases between tumor board and histological results, which could refine patient management strategies. We identified significant associations between hepatocellular carcinoma subtypes and recurrence rates, and found that molecular analysis based on frozen tumor samples is feasible in most cases and could be guided by the percentage of tumors cells on paraffin-embedded samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.